Please assess the completion status of the following clinical trial:

Trial Title: Topical Rapamycin to Erase Angiofibromas in TSC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be willing and able to comply with all trial requirements.~* Subject has a diagnosis of TSC and has visible facial angiofibromas.~* Female subjects of child bearing potential must not be pregnant and must agree to use appropriate contraceptive methods .~Exclusion Criteria:~* Subject is currently receiving therapy with Rapamycin.~* Subject is receiving any form of immunosuppression or has previously experienced immune dysfunction.~* Subject is currently participating in or has participated within the last 30 days in a clinical trial involving an investigational drug.~* Subject has a known hypersensitivity to either the vehicle or Rapamycin.~* Subject is a pregnant or nursing female.~* Subject has other dermatologic conditions that would preclude or prevent adequate assessment of changes to their facial angiofibromas.~* Subject has had laser surgery, cryotherapy, or other dermatologic treatment to their facial angiofibromas within the previous 6 months.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Cream only
- 0.1 % Rapamycin (Type: ACTIVE_COMPARATOR): 0.1% Rapamycin cream
- 1% Rapamycin (Type: ACTIVE_COMPARATOR): 1% Rapamycin cream

Based on this trial design, predict the completion outcome and termination type (if applicable).